Literature DB >> 9748052

Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q.

H Mori1, T Kondo, M Yokochi, H Matsumine, Y Nakagawa-Hattori, T Miyake, K Suda, Y Mizuno.   

Abstract

We report the results of pathologic and biochemical studies in a patient with 6q-linked autosomal recessive juvenile parkinsonism (AR-JP). Neuronal loss and gliosis were restricted to the substantia nigra and the locus ceruleus. No Lewy bodies were found, but neurofibrillary tangles and argyrophilic astrocytes were seen in the cerebral cortex and brainstem nuclei. The later findings, which have not been reported previously in AR-JP, suggest the pathologic heterogeneity of 6q-linked AR-JP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748052     DOI: 10.1212/wnl.51.3.890

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  81 in total

1.  Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects.

Authors:  M Periquet; C Lücking; J Vaughan; V Bonifati; A Dürr; G De Michele; M Horstink; M Farrer; S N Illarioshkin; P Pollak; M Borg; C Brefel-Courbon; P Denefle; G Meco; T Gasser; M M Breteler; N Wood; Y Agid; A Brice
Journal:  Am J Hum Genet       Date:  2001-02-14       Impact factor: 11.025

Review 2.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

3.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Authors:  Alexander Zimprich; Bertram Müller-Myhsok; Matthew Farrer; Petra Leitner; Manu Sharma; Mary Hulihan; Paul Lockhart; Audrey Strongosky; Jennifer Kachergus; Donald B Calne; Jon Stoessl; Ryan J Uitti; Ronald F Pfeiffer; Claudia Trenkwalder; Nikolaus Homann; Erwin Ott; Karoline Wenzel; Friedrich Asmus; John Hardy; Zbigniew Wszolek; Thomas Gasser
Journal:  Am J Hum Genet       Date:  2003-12-19       Impact factor: 11.025

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

5.  α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.

Authors:  Zane S Martin; Volker Neugebauer; Kelly T Dineley; Rakez Kayed; Wenru Zhang; Lindsay C Reese; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

6.  Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway.

Authors:  James A Olzmann; Lih-Shen Chin
Journal:  Autophagy       Date:  2007-10-15       Impact factor: 16.016

7.  Parkin mediates the degradation-independent ubiquitination of Hsp70.

Authors:  Darren J Moore; Andrew B West; Dustin A Dikeman; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

Review 8.  Progress in the pathogenesis and genetics of Parkinson's disease.

Authors:  Yoshikuni Mizuno; Nobutaka Hattori; Shin-Ichiro Kubo; Shigeto Sato; Kenya Nishioka; Taku Hatano; Hiroyuki Tomiyama; Manabu Funayama; Yutaka Machida; Hideki Mochizuki
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-06-27       Impact factor: 6.237

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.

Authors:  Helen C Ardley; Gina B Scott; Stephen A Rose; Nancy G S Tan; Alexander F Markham; Philip A Robinson
Journal:  Mol Biol Cell       Date:  2003-08-22       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.